VBI Vaccines Inc.
VBIV · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $7 | $1 |
| % Growth | 42.3% | -87.1% | 820% | – |
| Cost of Goods Sold | $3 | $3 | $3 | $3 |
| Gross Profit | -$2 | -$3 | $4 | -$3 |
| % Margin | -124.4% | -300.6% | 61.9% | -383.8% |
| R&D Expenses | $3 | $1 | $2 | $3 |
| G&A Expenses | $0 | $11 | $0 | $11 |
| SG&A Expenses | $8 | $8 | $9 | $11 |
| Sales & Mktg Exp. | $0 | -$2 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $4 | $0 |
| Operating Expenses | $10 | $10 | $14 | $14 |
| Operating Income | -$12 | -$12 | -$10 | -$37 |
| % Margin | -968% | -1,449.5% | -152% | -5,135% |
| Other Income/Exp. Net | -$6 | $12 | -$10 | -$8 |
| Pre-Tax Income | -$18 | -$0 | -$20 | -$45 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18 | -$0 | -$20 | -$45 |
| % Margin | -1,474.5% | -1.5% | -308.6% | -6,198.3% |
| EPS | -0.73 | -0.001 | -0.97 | -5.18 |
| % Growth | -145,900% | 99.9% | 81.3% | – |
| EPS Diluted | -0.73 | -0.001 | -0.97 | -5.18 |
| Weighted Avg Shares Out | 25 | 24 | 21 | 9 |
| Weighted Avg Shares Out Dil | 25 | 24 | 21 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $2 | $2 | $2 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$15 | $3 | -$18 | -$37 |
| % Margin | -1,268% | 296.4% | -270% | -5,135% |